Working with the guidance of an international, expert Scientific Advisory Board of breast cancer researchers and clinicians, and through growing collaborations with other breast cancer advocacy organizations in the US and internationally, LBCA provides a platform for invasive lobular carcinoma (ILC) research, maintains a library of current lobular breast cancer publications, and identifies clinical trials and research advocacy opportunities with a focus on lobular breast disease.  

As a clinician and/or researcher, you need the most relevant, up-to-date information for your patients and your work. We’re here to help by providing you with clinical peer-reviewed resources and an opportunity to query ILC expert clinicians and researchers.

ILC Publications Library

We’ve collected a library of published ILC research that is updated regularly.

Blog Posts

We’ve begun a blog series authored by the top ILC clinicians and researchers in the field.

Videos

We have an array of educational videos and podcasts, a collection of taped interviews with individuals or panels of clinicians or researchers on ILC- focused topics from past conferences, and videos on ILC Topics being discussed by our Scientific Advisory Board members available for viewing. Both you and your patients can review these trusted resources whenever is most convenient for you. 

Additional Resources

Here are additional resources that you or your patients may find helpful:

ILC Fact Sheet

Frequently Asked Questions

A list of Frequently Asked Questions (FAQs) about ILC is available for informational and educational purposes. 

You can download flyers for your office and share with patients. 

LBCA has created an ILC patient advocacy registry. If you are a researcher interested in learning more about how LBCA patient advocates can help support your ILC-specific grant, or about patient research advocates in your geographic area who may be able to assist you with ILC grant development and implementation activities, contact us at info@lobularbreastcancer.org.